Fostamatinib as a Single Agent or in Combination With Ruxolitinib for Treatment of Patients With Myelofibrosis With Severe Thrombocytopenia
Sponsor: Rigel Pharmaceuticals
Terminated
Low accrual
Other terminated trials from Rigel Pharmaceuticals
Other Myelofibrosis trials with similar outcome
A PHASE2 clinical study on Myelofibrosis and Thrombocytopenia, this trial is terminated or withdrawn. The trial is conducted by Rigel Pharmaceuticals and has accumulated 11 data snapshots since 2021. Longitudinal tracking of this trial contributes to a broader understanding of treatment development timelines.
Status Flow
Change History
11 versions recorded-
Sep 2025 — Present [monthly]
Terminated PHASE2
-
Sep 2024 — Sep 2025 [monthly]
Terminated PHASE2
-
Jul 2024 — Sep 2024 [monthly]
Terminated PHASE2
-
Jan 2024 — Jul 2024 [monthly]
Terminated PHASE2
-
May 2023 — Jan 2024 [monthly]
Terminated PHASE2
Status: Recruiting → Terminated
▶ Show 6 earlier versions
-
Nov 2022 — May 2023 [monthly]
Recruiting PHASE2
-
Jun 2022 — Nov 2022 [monthly]
Recruiting PHASE2
-
Jun 2021 — Jun 2022 [monthly]
Recruiting PHASE2
Status: Not Yet Recruiting → Recruiting
-
Mar 2021 — Jun 2021 [monthly]
Not Yet Recruiting PHASE2
-
Jan 2021 — Mar 2021 [monthly]
Not Yet Recruiting PHASE2
-
Oct 2020 — Jan 2021 [monthly]
Not Yet Recruiting PHASE2
First recorded
Eligibility Summary
No eligibility information available.
Contact Information
- Rigel Pharmaceuticals
- Washington University School of Medicine
For direct contact, visit the study record on ClinicalTrials.gov .